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Introduction
Multiple sclerosis (MS) is a chronic inflammatory and demyelinating neurodegenerative disorder, characterized pathologically by central nervous system (CNS) alterations in the vasculature, inflammatory infiltrates, demyelination, glial scarring, oligodendrocyte loss, and axonal damage and loss (Frohman et al., 2006) . The irreversible axonal loss and neurodegeneration are thought to be the major correlate of chronic disability (Bjartmar and Trapp, 2003) and likely starts early in disease (Ferguson et al., 1997; Trapp et al., 1998) .
Approved disease modifying therapies (DMTs) target inflammatory processes and fall into two groups: those well tolerated but with partial efficacy, or those with greater efficacy and increased risk profiles (Kieseier et al., 2011; Stuve, 2009 ). Development of orally efficacious, safe, and well-tolerated therapeutics with immunomodulatory and neuroprotective properties remains a priority.
In experimental autoimmune encephalomyelitis (EAE), the mouse model of MS, autoreactive T cells that produce pro-inflammatory cytokines including tumor necrosis factor α (TNFα), interferon-γ (IFNγ), interleukin (IL)-17, and granulocyte macrophage colony stimulating factor (GM-CSF), travel to the CNS to cause disease (Sospedra and Martin, 2005) .
Both CD4 and CD8 T cells may contribute directly to pathogenesis via direct contact, but phenotypical and molecular profiles vary and define pathogenic or suppressive/regulatory roles (Hauser et al., 2008; Johnson et al., 2010; Racke, 2009) . While demyelination and associated axonal loss appear secondary to inflammation (Trapp et al., 1998) , neurodegeneration seen prior to inflammatory cell infiltration in EAE and the progressive loss of function after the inflammatory phase has subsided (Hobom et al., 2004; Qi et al., 2006) seem distinct. Recent findings implicate mitochondrial dysfunction secondary to energy imbalance and increases in reactive oxygen species (ROS) as sources of oxidative damage not directly attributable to inflammation (Mahad et al., 2015; Mahad et al., 2009; Su et al., 2009 ).
Emerging evidence implicates ROS and reactive nitrogen species (RNS), focusing on superoxide, nitric oxide, and their intermediates, as contributors to several mechanisms underlying the pathogenesis of MS and EAE (Gilgun-Sherki et al., 2004; Gonsette, 2008a) . ROS drive morphological alterations that promote leukocyte traffic across the blood-brain barrier (BBB) (Schreibelt et al., 2006; Van der Goes et al., 2001) . Infiltrated leukocytes produce ROS that induce myelin phagocytosis and, therein, myelin breakdown by macrophages, oligodendrocyte damage, as well as axonal and neuronal injury and loss (Smith et al., 1999; Smith et al., 2001 ; van Meeteren et al., 2004) . Microglia and neurons generate peroxynitrite, a principal mediator of the oxidative stress and excitotoxicity that drives neurodegenerative processes in MS (Gonsette, 2008b; Torreilles et al., 1999) .
Nitroxide radicals exhibit antioxidant activity and have been reported to react with both ROS and RNS, directing a shift from their use as biophysical tools to potential therapeutics (Soule et al., 2007b) . Nitroxides are flexible, cycling via redox transformation between the oxidation states of nitroxide radical, hydroxylamine, and the oxoammonium cation ( Fig.   1A ) (Soule et al., 2007a) , as they interact with biological oxidants and reductants. TEMPOL (4-hydroxy-2,2,6,6-tetramethylpiperidine-N-oxyl) is a small (MW 172Da) stable nitroxide radical that can readily permeate biological membranes (Bonini et al., 2002) , allowing for significant tissue and intracellular accumulation. Indeed, TEMPOL exerts beneficial effects in animal models of shock, hypertension, diabetes, ischemia-reperfusion injury, spinal cord injury, traumatic brain injury (Deng-Bryant et al., 2008; Kato et al., 2003; Schnackenberg and Wilcox, 2001; Sledzinski et al., 1995; Thiemermann, 2003) , and neurodegenerative models for Alzheimer's and Parkinson's disease (Ghosh et al., 2008; Lipman et al., 2006) . The current study demonstrates that oral TEMPOL limits CNS inflammation both prophylactically and therapeutically in the most established models of MS. Through immunomodulation and deviation away from an inflammatory phenotype, TEMPOL reduces expression of inflammatory mediators and markers both outside and within the target organ, while enriching for regulatory populations.
In this regard, oral TEMPOL affords neuroprotection through several distinct immunomodulatory mechanisms that have not previously been characterized or associated with modes of action for nitroxide radicals. Ultimately, the overall outcome is substantial protection from disability in a setting of neuroinflammation.
Methods

EAE induction
All experiments were carried out in compliance with the Guide for the Care and Use of Laboratory Animal Resources (1996) , the Canadian Council on Animal Care guidelines and approved by the NINDS Animal Care and Use and UBC Animal Care Committees. Female C57BL/6J (Jackson Labs) or SJL/J (Harlan Laboratories) mice were acclimatized at least one week prior to study and then used as models of active chronic and passive relapsing-remitting model of MS, respectively. 8-10 week old C57BL6/J mice were immunized with 200 µg MOG35-55 (MEVGWYRSPFSRVVHLYRNGK; Stanford Pan Facility, Stanford CA) as described previously (Quandt et al., 2012) . For passive disease, animals were immunized with 75 µg PLP139-151 (HCLGKWLGHPDKF, Stanford Pan Facility) and draining lymph node (LN) cells enriched with PLP before transfer to healthy recipients as described (Anderson et al., 2004) .
Animals were monitored daily for clinical signs at least through the first attack of disease and through the first days of recovery (typically day 30-35) or longer in chronic studies to day 45 or 60 according to the scoring table and clinical symptoms outlined in Table 1 .
Quantification of TEMPOL
Mice that were given TEMPOL in their drinking water at a concentration of 58 mM lived longer secondary to lower tumor incidence and maintained a normal healthy weight, while sucrose-fed controls gained substantial weight (Mitchell et al., 2003) . Powdered TEMPOL was uniformly mixed with mouse chow by a "cold press" technique (Bio-Serv, Frenchtown, NJ) at 10 g/kg of chow (the equivalent to 58 mM supplied in drinking water) and was found to reduce body weight without toxicity, decrease cancer, and extend survival when administered after nonlethal total body radiation (Mitchell et al., 2012) . This dose was applied in our study. Purina 4501 chow (Bio-Serv) with or without 10 g/kg TEMPOL (Sigma Aldrich, St. Louis, MO) was given ad libitum. For detection of TEMPOL in blood and tissue samples, animals were euthanized with CO 2 and analyzed as described previously (Hyodo et al., 2006) . Blood and whole brain tissue samples were diluted and homogenized and ferricyanide added prior to measurement on a Varian E-9 X-band electron paramagnetic resonance spectrometer and compared to standard curves.
Histology
Animals were perfused following anesthesia with a Ketamine/Xylazine mixture (87.5 mg/kg Ketamine and 12.5 mg/kg Xylazine) prior to thoracotomy and PBS perfusion via the left ventricle followed by 4% paraformaldehyde (PFA) in PBS. The brain and spinal column were removed to 10% neutral buffered formalin for 5 days. The entire spinal column from each animal was trimmed, decalcified, and cut into ten equal lengths of 5 mm. Six µm sections were cut starting at the "top" of each section and stained with hematoxylin and eosin (H&E), Luxol fast blue (LFB, for myelin), and silver Bielshowsky (axonal) staining (Histoserve, Gaithersburg, MD). Sections were scored according to the number and degree of infiltration as outlined in Table 2 .
Flow cytometry
PBS-perfused spinal cords were flushed from columns and a single cell suspension representing infiltrates from the entire cord in 30% Percoll (GE Healthcare, Uppsala Sweden) were layered over 70% Percoll and mononuclear cells were recovered and stained with antibodies in staining buffer (5% FBS in PBS, 0.05% sodium azide) and run on a BD FacsCalibur for analysis with CellQuest software (BD).
Lymphoid organ cell culture
Animals were anesthetized using CO 2 followed by cervical dislocation. Spleens and inguinal, brachial, and axillary LN were removed and single cell preparations red cell-depleted with Ammonium-Chloride-Potassium Lysing Buffer (Life Technologies, Carlsbad, CA). Cells were immediately set into culture or stained for flow cytometry as above. Intracellular staining with Foxp3 and IgG2a isotype control antibodies was performed using the Mouse Regulatory T Cell Staining Kit #2 (eBioscience, San Diego, CA). Cells were examined on a Miltenyi MacsQuant flow cytometer and analyzed using FlowJo (version 7.6.5; Treestar, Ashland, OR) 
MOG-specific antibody ELISA
Blood collected from the submandibular vein was processed for serum and stored at -20°C. Micro-titre plates (Greiner Bio-one, Munroe, NC) were coated with 2 µg/mL MOG35-55 prior to incubation with sera. Secondary antibodies [goat anti-mouse IgG-peroxidase (Jackson ImmunoResearch Laboratories Inc., West Grove, PA), goat anti-mouse IgG1-biotin, IgG2a-biotin, or IgG2c-biotin (Sigma-Aldrich)]) and streptavidin-HRP enabled chromogenic conversion of TMB and quantification as for cytokine ELISAs.
Neurofilament ELISA
A sandwich ELISA to detect normal neurofilament H (phosphorylated heavy chain) levels was performed as previously described (Petzold and Shaw, 2007) . SMI35R monoclonal antibody (to neurofilament heavy chain, Covance Princeton, NJ)-coated microtitre plates were incubated with 15 µg of spinal cord protein; protein was detected with rabbit polyclonal anti-neurofilament H antibody (N-4142; Sigma) and horseradish peroxidase-conjugated anti-rabbit immunoglobulin.
Statistical evaluation
Statistical evaluation of significant differences between groups was performed using one-way analysis of variance (ANOVA) with subsequent multiple comparison analysis. When comparing TEMPOL to control groups in EAE disease or for infiltrates, neurofilament, or antibody we applied the Mann-Whitney nonparametric ranking test or T test when data were normally distributed. Significance is reported as *** p < 0.001, ** p < 0.01, and * p < 0.05. For flow cytometry population and cell surface marker analyses we applied Bonferroni corrections for the populations analyzed and for the separate T cell subset analyses. All analyses were performed using SigmaPlot (Version 11.0, Systat Software, Inc.) and graphs prepared with GraphPad Prism 5.
Results
TEMPOL protects against actively-induced EAE
Animals were placed on TEMPOL or control chow for 2 weeks, immunized, and euthanized 10 days later to quantify TEMPOL. The hydroxylamine (reduced) form of TEMPOL could be detected at 3.0 ±1.9 to 5.0 ±1.5 nmol/kg tissue in the brains and 10.6 ±4.9 to 40.4 ±14.5 nmol/mL (µM) blood in C57BL/6J and SJL/J animals respectively (n = 3 per group). TEMPOL reduced the incidence (27% vs. 93% in control-diet animals) and delayed disease onset (Fig. 1B) .
Average daily scores were lower in TEMPOL-fed mice compared to controls, from day 13 and on. TEMPOL decreased the total disease burden/cumulative disease over the course of the experiment (5.8 ± 2.6 vs. 29.9 ± 2.8 in control diet animals).
Histologically, there were fewer immune cells within spinal cords of TEMPOL-fed animals (Fig. 1C) . TEMPOL-fed EAE mice showed fewer infiltrates extending into the parenchyma and lesser involvement of parenchymal vessels compared to controls ( Fig. 1C; 1.73 ± 0.19 in control vs. 1.04 ± 0.24 in TEMPOL-fed animals p = 0.002, Fig. 1D ). Infiltrates were absent in 40% of TEMPOL-fed animals examined at 10 different levels of the spinal cord; every control animal showed infiltrates in more than 50% of levels examined (data not shown).. CD11b high/CD45 dim microglia from control-fed EAE animals showed greater IAb/MHC class II than levels of the isotype control ( Fig. 2B ), whereas no samples from TEMPOL-fed animals showed IAb staining greater than that of the isotype control.
Immunomodulation in TEMPOL-fed animals
In both LN and spleens of TEMPOL-fed EAE mice, ex vivo proliferative responses to MOG, anti-CD3, or Con A (Fig. 3A ,B) were comparable to controls. Ex vivo proliferation was also examined using cells isolated from age-matched healthy mice administered control or TEMPOL chow for 28 days. Similar to EAE mice, polyclonal responses to Con A or anti-CD3 measured ex vivo were not reduced by TEMPOL administration (data not shown).
Both IFNγ and TNFα production by anti-CD3-stimulated cells was significantly lower in isolates from TEMPOL-fed EAE animals ( Fig. 3C,D) . GM-CSF production also tended to be lower (p = 0.090) but was not significant (data not shown). Interestingly, IL-10 production also tended to be greater by TEMPOL-fed animals (p = 0.087). Responses to Con A were also significantly different between control and TEMPOL-fed animals: production of IL-2 and IL-10 by cells from TEMPOL-fed animals was significantly lower than controls (Fig. 3E,F) . While
IFNγ production also tended to be lower in TEMPOL-fed animals, (p = 0.059), IL-17 levels were similar between groups and IL-4 and TGF-β1 were also similar but below the limit of detection.
Fewer differences were noted in spleen samples; lower IL-2 production by MOGstimulated cells from TEMPOL-fed animals was the only significant difference (p = 0.035).
Cytokine production was also examined in supernatants from spleens of healthy mice fed a control or TEMPOL diet; only TGF-β1 levels were different (lower) in TEMPOL-fed animals following the addition of Con A to cells (p = 0.018).
The generation of MOG-specific antibodies is thought to contribute to disease in rodent models of MS (Dittel, 2000) , and to a greater extent the disease process in MS (Reindl et al., 1999) . TEMPOL-fed EAE mice showed increased levels of MOG-specific serum IgG (Fig. 4A ).
This increase was predominantly in the IgG1 isotype group typically associated with a T H 2 response ( Fig. 4B) . Similarly, the IgG2c levels associated with more pro-inflammatory T H 1 responses tended to be reduced in TEMPOL-fed animals ( Fig. 4C ), and drove IgG1:IgG2c ratios (Fig. 4D ).
TEMPOL alters T cell subset distributions
While no significant differences were observed in the relative proportions of T, B, myeloid, dendritic, or NK subsets between control or TEMPOL-fed EAE animals ( More CNS infiltrates were recovered from control-fed EAE mice than those fed TEMPOL (Table 3) . Control-fed animals had greater proportions of CD45 cells and CD11b and CD3 + T cell populations also tended to be greater than in TEMPOL-fed mice. Notably, the CD8 enrichment apparent in lymphoid organs was also detected in CNS isolates, where CD4/CD8 ratios dropped significantly from 4.9 ±0.8 to 1.7 ±0.1 in TEMPOL-fed animals.
CD4 + T reg cell (CD4 + CD25 + Foxp3 + ) populations tended to increase from 9.7 to 12.3% of CD4 + T cells in LN of TEMPOL-fed compared to control-fed EAE mice. CD8 + T reg cells also tended to be higher in LN, but still made up less than 1% of the CD8 + T cell population (data not shown). This increase in regulatory populations was not observed in the spleen, where the numbers of T reg cells in the CD4 + subset were slightly lower in TEMPOL-fed animals than controls (8.8 vs. 10.2% of the CD4 + population respectively, p = 0.045). Notably, CD8 T cells and CD4 T reg populations were both significantly greater in TEMPOL-fed than control-fed healthy mice (Table 4) .
TEMPOL influences antigen presenting and co-stimulatory molecule expression
Expression of MHC class II, CD40, CD80, and CD86 was examined in myeloid cells, CD86 expression tended to be higher in myeloid cells of both the LN and spleen of TEMPOL-fed animals. Notably, CD80 expression was also significantly increased with TEMPOL in myeloid DC within LN. MHC I expression was also studied, but was not found to be altered (data not shown).
Surface molecule expression was also studied in healthy mice on control or TEMPOL chow. There were no differences observed in LN, but MHC II also tended to be lower in 
TEMPOL limits disability when given after disease induction
Animals fed TEMPOL starting 7 days after immunization (Fig. 5A ) on average had milder disease (0.52 ± 0.63 vs. 1.72 ± 0.89, p = 0.03) and a lower peak disease severity (1.09 ± 1.0 vs. 3.0 ± 1.58; p = 0.05) than controls. TEMPOL also reduced disease incidence compared to controls (50 vs. 100% respectively). To test therapeutic efficacy, a subset of EAE animals were switched to TEMPOL chow at the onset of clinical symptoms (first sign of a limp tail or paresis; grade 1 or greater) (Fig. 5B) . Cumulative disease scores from the start of TEMPOL administration through to experiment end were reduced in TEMPOL-fed animals (36.9 ± 2.9 vs.
50.3 ± 4.3 in controls; p = 0.004) consistent with the reduction in average disease score over the same time (1.8 ± 0.1 in TEMPOL-fed vs. 2.5 ± 0.2 in controls, p = 0.004). Average disease scores differed significantly between control and TEMPOL-fed animals from day 19 until the study end (p < 0.05).
To distinguish the protective effects of TEMPOL from effects on the generation of autoreactive T cells, passive disease was examined following the transfer of primed encephalitogenic T cells (Fig. 5C ) into animals that received TEMPOL feed for two weeks and through the duration of the study. While the day of onset was similar, the peak severity of disease was significantly reduced in TEMPOL-fed mice (3.85 vs. 2.81 respectively, p = 0.011).
Protection lasted 45 days, whereby TEMPOL reduced the average cumulative disease score by more than half (78.8 vs. 33.9 in control-fed mice, p = 0.00046). To further examine the potential for TEMPOL to treat established disease, we also performed a study where animals were transferred from control to TEMPOL feed after the onset of clinical disease (Fig. 5D ). TEMPOL did not significantly reduce the cumulative disease scores over the time of this shorter study (28.38 ± 6.07 vs. 42.65 ± 6.04, p = 0.068 with TEMPOL vs. control chow respectively), but similar to the treatment of established active disease in Fig.5B average disease scores were significantly lower in TEMPOL-fed animals than controls (1.38 ± 0.27 vs. 2.31 ± 0.28, p = 0.026) over the treatment period.
Infiltrates were assessed at or near peak disease in an experiment similar to that in Fig.   5C . TEMPOL-fed animals showed fewer infiltrates extending beyond the meninges or involving the parenchyma (Fig. 5E ). Typical infiltrates in controls extended well beyond the meninges (3.25 ± 0.15), were numerous throughout the cord, and were typically associated with areas of reduced Luxol fast blue-stained myelin (see arrows) ( Fig. 5F ). In contrast, TEMPOL-fed animals had fewer infiltrates overall (1.76 ± 0.21, p < 0.0001), rarely extending beyond the meningeal interface (see arrows) and with relative preservation of myelin staining. Neurofilaments are major proteins of neurons and are particularly concentrated in axons. To assess whether there was a relative loss of axons, the relative amount of healthy or normal neurofilament H (phosphorylated/heavy neurofilament of axons) was measured (Fig. 5G) . TEMPOL-fed animals showed significantly higher levels of neurofilament H in their spinal cords, suggesting that this axon-associated protein was preserved in these mice compared to control fed EAE animals (p = 0.03).
Discussion
Our study is the first to show that oral administration of the antioxidant TEMPOL, alone, both prophylactically and therapeutically limit CNS autoimmune disease and damage in the most established models of MS. Animals on TEMPOL were spared from severe clinical disease, and showed little evidence of microglial activation, one of the earliest indicators of insult to the CNS that often precedes infiltration and clinical disease in EAE (Kreutzberg, 1996; Ponomarev et al., 2005 ). Our studies demonstrate potent immunomodulatory properties of TEMPOL that have not been described previously. At doses associated with efficacy in a complex disease model, we describe immune deviation from an inflammatory phenotype evidenced by cytokine shifts, antibody profile changes, and reductions in antigen-presenting molecules. Additionally, TEMPOL administration is associated with changes in T cell subsets, most notably an increase in CD4+ regulatory T cell populations.
Our studies clearly show that TEMPOL does not limit adaptive immune responses, but instead alters the nature of that response. Immune-mediated diseases can often be treated with immunosuppressive therapies, which function by globally limiting immune responses (Bach, 1993) . While effective, immunosuppression leaves a patient vulnerable to potentially lifethreatening infections. Mitoxantrone (Novantrone), for example, suppresses proliferation of T cells, B cells, and macrophages (Hartung et al., 2002) . Teriflunomide (Aubagio) is a newer oral MS therapy that also inhibits T cell proliferation and activation (Warnke et al., 2009 ). Both ameliorate EAE, (Edan et al., 2004 ) yet while teriflunomide is relatively safe compared to mitoxantrone in terms of toxicity, it still carries a risk of opportunistic infections (Warnke et al., 2009 ). TEMPOL does not limit antigen-specific responses, and may indeed enhance CD8 + T cell-mediated responses. Notably, TEMPOL enhanced T cell proliferation in vitro at doses matching those measured in animals benefitting from oral TEMPOL (data not shown) and is similar to uric acid, which was also found to be beneficial in EAE (Kean et al., 2000) .
Fundamentally, the immune deviation observed following TEMPOL administration is the central driver of its immunomodulatory and protective properties. TEMPOL was associated with lesser IFNγ, TNFα, and TGF-β1 production in EAE animals. IFNγ and TNFα promote an inflammatory T H 1-type immune response that leads to ROS and RNS production, cytotoxicity, and tissue injury (Kopf et al., 2010) . Both IFNγ and TNFα have been implicated in disease progression in MS, as well as in other immune-mediated diseases (Benveniste and Benos, 1995) .
In the CNS, TNFα is observed within active lesions and in the CSF of people with MS, and is associated with BBB disruption (Benveniste and Benos, 1995) . In vitro, TNFα has been shown to mediate damage to myelin and oligodendrocytes (Selmaj and Raine, 1988) . IFNγ induces expression of MHC II, and has been shown to exacerbate MS when administered to patients (Benveniste and Benos, 1995) .
Collectively, decreased production of these cytokines indicates a prototypical shift from a pro-inflammatory T H 1 response towards a more immunosuppressive or T H 2 type response.
Driving such a shift has long been proposed to have beneficial effects in MS, and is the functional mechanism of the immunomodulatory therapy glatiramer acetate (Oreja-Guevara et al., 2012). Our cytokine data are supported by the observed differences in MOG-specific serum
IgG antibodies: TEMPOL-fed EAE mice had increased levels of the T H 2-associated IgG1 and decreased levels of the T H 1-associated IgG2c isotype (Stevens et al., 1988 ). (Huynh et al., 1995 against spontaneous malignant tumours, as they are able to detect abnormal cells (Andersen et al., 2006) . In general increases in CD8 + T cells could provide a "boost" to the immune system in the form of enhanced protection against pathogens. An increase in CD8 + T cells may even explain other benefits associated with TEMPOL, as CD8 + T cells are primary players in antitumor responses and mice on long term TEMPOL are less likely to develop tumours, and therein live longer than control-fed mice (Mitchell et al., 2003) .
Importantly, TEMPOL's effects are not limited to an influence on the priming of pathogenic autoreactive T cells. Our study of disease in SJL animals, where encephalitogenic cells are primed outside of the animal, demonstrates TEMPOL's ability to afford protection against activated autoreactive populations known to traffic to, and thereby illicit damage and disease within the CNS. T cells can mediate neuronal/axonal damage directly, or facilitate pathology through recruitment of macrophages and their complement of oxidative stressors and other soluble mediators. In this passive model, it has been well-characterized that changes in the BBB and alterations within the CNS attributed to autoreactive T cells begin to occur as early as 5-7 days post T cell transfer, well before the onset of clinical symptoms (Chakrabarty et al., 2003; Smorodchenko et al., 2007; Wuerfel et al., 2007) . Preliminary studies in our lab show that initiating oral TEMPOL as early as 7 days post disease induction, differences are observed as soon as 4 days later by CNS microarray analysis of control vs. TEMPOL-fed animals, suggesting TEMPOL is able to alter the earliest events in CNS-specific autoimmunity (data not shown).
Indeed, other groups have shown TEMPOL to be well-tolerated and orally efficacious in animals, with potential health benefits beyond the treatment of disease (Mitchell et al., 2003) .
While our study documents immunomodulatory properties of TEMPOL in the periphery and suggests they occur within the CNS, additional mechanisms may also serve to limit CNS damage. In our study, TEMPOL was detected in tissues after 24 days on TEMPOL chow, but was not examined earlier. i.p. administration of TEMPOL (24 mg/kg) in a demyelinating mouse hepatitis virus model resulted in TEMPOL measurements around 15 µm by 10 minutes after administration (Tsuhako et al., 2010) . Lowering of TEMPOL to 3 µM in EAE mice was deemed secondary to TEMPOL's reacting with radicals resulting from viral infection. In the same study, TEMPOL administered daily i.p. as well as in the drinking water from the time of viral inoculation showed a reduction in subsequent demyelinating disease severity in this model of encephalomyelitis (Tsuhako et al., 2010) . The authors observed reduced mortality associated with lower viral load, reduced infiltration, and less BBB breakdown, but this efficacy was only demonstrated prophylactically. This reduction may be attributed to alterations in the anti-viral response or protection at the level of the CNS; the study design did not allow for distinction. In this model of disease, with rapid significant morbidity and mortality secondary to viral attack, it is difficult to discern which steps in viral pathogenesis are of direct relevance to MS.
Administration of TEMPOL orally is not only simple but appears to evade several of the deleterious effects observed following i.v. or bolus injections of TEMPOL. In studies requiring a high dose i.v. administration to achieve therapeutic efficacy, a significant lowering of blood pressure is noticed. One study has described the ability of a similar nitroxide radical, Tempamine, to modulate autoantigen-driven EAE. Importantly, TEMPOL was only effective
prophylactically and only when encapsulated in a liposomal structure delivered i.v. (Kizelsztein et al., 2009 ). Free Tempamine had no effect, thought to be quickly eliminated from plasma. After optimization, they showed only a modest ability to limit the development of mild disease in a therapeutic manner, and ultimately found methylprednisolone to be far superior to the Tempamine formulation (Turjeman et al., 2015) . Notably, Tempamine reduced the proliferation of LN cells isolated from EAE mice and assayed in vitro, and is perhaps an important difference in mechanisms of action between the two formulations.
The separation of anti-inflammatory and neuroprotective effects of TEMPOL in EAE models is simplified, if one considers neurodegeneration to occur largely only secondary to inflammation. Our studies clearly show that limiting inflammation limits disability in this model.
Notably, the efficacy of TEMPOL in models of "classic" or less inflammation-associated neurodegenerative disease is already well described (Ghosh et al., 2008; Lipman et al., 2006) .
With the ability to permeate cell membranes and scavenge superoxide and peroxynitrite, TEMPOL could indeed limit inflammatory demyelinating disease by scavenging both inflammatory by-products in the tissue and free radicals within cells experiencing mitochondrial dysfunction. Evidence for a pathogenic role for ROS in MS and EAE stems from the beneficial effects of antioxidants on disease models (Carlson and Rose, 2006) . ROS play important physiological roles in cellular regulatory processes (Fialkow et al., 2007) (Gonsette, 2008b; Torreilles et al., 1999) .
In cellular analyses, TEMPOL has well-characterized SOD mimetic and O 2 -scavenging activity (Krishna et al., 1992; Mitchell et al., 1990) with an ability to catalytically convert the O 2 -radical to H 2 O 2 and O 2 . Moreover, TEMPOL protects cells against damage from exposure to hypoxanthine/xanthine oxidase or H 2 O 2 in vitro with greater efficacy than exogenously supplemented catalase or SOD itself (Samuni et al., 1991a; Samuni et al., 1991b) . As well it can rapidly decompose ONOO−-derived free radicals nitrogen dioxide and carbonate to which ONOO−-mediated tissue damage in MS are attributed (Carroll et al., 2000) . Given the evidence for increased levels of ROS and RNS in MS either prior to or secondary to inflammatory processes, or secondary to mitochondrial dysfunction occurring independent of inflammation (Andrews et al., 2005) , oral TEMPOL becomes a strong therapeutic candidate in MS as it achieves fully effective concentrations in tissues where it could exert antioxidant and protective actions (Wilcox, 2010) . Such protective effects at the level of the target tissue may indeed contribute to the ability of TEMPOL to treat established EAE in both active and passive models of EAE.
The most desirable therapies for MS would stop disease development at the earliest stages, limiting inflammation and the related axonal loss and neurodegeneration that are associated with disability, but also have the potential to limit disease processes already underway. In these regards, the oral administration of TEMPOL provides a favourable alternative to current therapies, and thus represents an important therapeutic agent for further evaluation in the treatment of MS.
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